FDA clears PositiveID's iglucose system

Delray Beach, FL-based PositiveID has received FDA clearance for its iglucose mobile health system for diabetes management. The system uses mobile technology to help diabetics manage their condition by communicating glucose readings from data-capable glucometers to the iglucose management portal.

The iglucose system collects and transmits stored data from a variety of blood glucose meters, including Johnson & Johnson's ($JNJ) LifeScan OneTouch and Nipro Diagnostic True monitoring systems, to a secure database by wireless cellular technology.

Over the coming months, the company plans initial roll-outs with several partners. PositiveID already has the wireless infrastructure in place through partnerships with AT&T in the U.S. and Rogers Communications in Canada, and will look to add additional wireless partners.

"iglucose is a safe, flexible, convenient, cost-effective and straightforward solution that we believe will revolutionize the way people with diabetes manage their condition," explains company CEO William Caragol in a statement. "iglucose represents an opportunity to help decrease costs to our healthcare system by helping to improve disease management and patient compliance. This FDA clearance is an important validation of our product offering for PositiveID and we will work diligently to make iglucose available to everyone affected by diabetes in the near future."

PositiveID is focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. It was formed in November 2009 through the merger of VeriChip Corporation and Steel Vault Corporation, according to the company's website.

The company has worked with a number of big names in the pharma and medical devices industries. Early last month, it announced that its iglucose will be used in a diabetes study sponsored by the American Medical Directors Association Foundation and supported by Sanofi ($SNY).

- see the PositiveID release

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.